Research ArticleGraft-Versus-Host Disease

Donor fecal microbiota transplantation ameliorates intestinal graft-versus-host disease in allogeneic hematopoietic cell transplant recipients

See allHide authors and affiliations

Science Translational Medicine  12 Aug 2020:
Vol. 12, Issue 556, eaaz8926
DOI: 10.1126/scitranslmed.aaz8926

You are currently viewing the editor's summary.

View Full Text

Log in to view the full text

Log in through your institution

Log in through your institution

FMT fires up treatment of GvHD

Allogeneic hematopoietic cell transplantation (HCT) is a beneficial treatment for hematological malignancies. However, HCT can lead to graft-versus-host disease (GvHD), which affects various organs including the gut. Fecal microbial transplantation (FMT) from allogeneic donors has successfully treated intestinal disorders such as Clostridium difficile infection and ulcerative colitis. van Lier et al. conducted a single-arm clinical trial to investigate whether allogeneic FMT could ameliorate symptoms of intestinal GvHD in 15 HCT recipients. Within a month of treatment, intestinal GvHD resolved and gut microbial diversity was restored in 10 of 15 study participants. Although confirmation is required in larger trials, allogeneic FMT may be a promising treatment for intestinal GvHD.

View Full Text

Stay Connected to Science Translational Medicine